scispace - formally typeset
M

Mamoun Younes

Researcher at University of Texas Health Science Center at Houston

Publications -  159
Citations -  6531

Mamoun Younes is an academic researcher from University of Texas Health Science Center at Houston. The author has contributed to research in topics: Adenocarcinoma & Cancer. The author has an hindex of 41, co-authored 149 publications receiving 6114 citations. Previous affiliations of Mamoun Younes include Yale University & National Institutes of Health.

Papers
More filters
Journal ArticleDOI

Overexpression of glut1 and glut3 in stage I nonsmall cell lung carcinoma is Associated with poor survival

Mamoun Younes, +4 more
- 15 Sep 1997 - 
TL;DR: The aim of this study was to determine the biologic significance of Glut1 and Glut3 overexpression in Stage I NSCLC.
Journal Article

Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers

Mamoun Younes, +4 more
- 01 Mar 1996 - 
TL;DR: Using immunohistochemistry, it is found that Glut1 is largely undetectable in normal epithelial tissues and benign epithelial tumors but is expressed in a significant proportion of a variety of human carcinomas.
Journal ArticleDOI

Estrogen Receptor β

Mamoun Younes, +1 more
- 01 Jan 2011 - 
TL;DR: The clinical significance of ER-B expression in tumors other than breast is currently under investigation, and pathologists need to be more aware of this increasingly important protein, as it will soon find its way into routine clinical practice.
Journal ArticleDOI

Clinical Importance of Estrogen Receptor-β Evaluation in Breast Cancer Patients Treated With Adjuvant Tamoxifen Therapy

Naoko Honma, +9 more
- 01 Aug 2008 - 
TL;DR: Immunohistochemical examination of ER-beta1 in addition to ER-alpha and PR is clinically important in patients with breast cancer treated with tamoxifen monotherapy, and positively staining for ER- betaN or ER-Beta1 was associated with significantly better survival.
Journal ArticleDOI

MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival

Bei Zheng, +17 more
- 01 Aug 2003 - 
TL;DR: Inhibition of the upstream MAPK kinase (also called MEK) by the small molecule UO126 inhibited the phosphorylation of ERK and demonstrated a dose- and time-dependent antiproliferative activity in HD cell lines, providing a proof ofprinciple that inhibition of the MEK/ERK pathway may have therapeutic value in HD.